Marketing-authorisation holder · Germany
Leadiant Gmbh
2 medicines in 2 countries, as authorisation holder.
Loading…
Marketing-authorisation holder · Germany
2 medicines in 2 countries, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
2 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ÁCIDO QUENODESOXICÓLICO LEADIANT 250 MG CÁPSULAS DURAS250 mg mg · Cápsula dura | Quenodesoxicolico acido | Spain | Marketed | 2019 |
| Chenodeoxycholic acid Leadiant (previously Chenodeoxycholic acid sigma-tau) | Chenodeoxycholic acid | EU (EMA) | Authorised | 2017 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 1 | 1 | 0 | CompaniesAll medicines |
| European Union (EMA) | 1 | 1 | 0 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM otros; source update 2026-09-16; acquired 2026-10-08.
Licence: CC BY-SA 4.0
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM, CIS_MITM.txt, published 13/10/2026, acquired 2026-10-25T22:15:46.803459+00:00; exact facts retained, no endorsement.
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Report an error or request removalCorrections from the company itself are welcome.
Keep Leadiant Gmbh’s medicines accurate on Prognia, see how professionals use them and answer what they ask. A 20-minute call, in English.
Book a callRanked by their number of medicines.